CRISPR Therapeutics AG (CRSP)’s Casgevy Expands Global Adoption in 2025

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. CRISPR Therapeutics AG stands among them.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneering biotech company focused on gene-editing medicines using CRISPR/Cas9 technology. Its flagship therapy, Casgevy, is an ex vivo CRISPR-based treatment for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), with global adoption expanding rapidly. As of mid-2025, over 75 authorized treatment centers are operational, and more than 90 patients have undergone cell collection, with new initiations expected to grow throughout the year.

In 2025, CRISPR Therapeutics AG (NASDAQ:CRSP) also reported encouraging Phase 1 results for CTX310, an in vivo gene-editing candidate targeting ANGPTL3, a gene involved in regulating LDL cholesterol and triglycerides. The therapy demonstrated dose-dependent reductions of up to 86% in LDL and 82% in triglycerides with a favorable safety profile, addressing a significant unmet need in cardiovascular disease. Full Phase 1 data are anticipated in the second half of 2025, potentially validating the business’ in vivo liver editing platform. These advances have helped CRISPR Therapeutics emerge among the best performing stocks in the biotech sector.

CRISPR Therapeutics AG (CRSP)’s Casgevy Expands Global Adoption in 2025

Beyond blood disorders and cardiovascular disease, CRISPR Therapeutics AG (NASDAQ:CRSP) is advancing its oncology and autoimmune pipeline. Two next-generation CAR-T candidates, CTX112, targeting CD19, and CTX131, targeting CD70, are progressing through clinical development, with updates expected later this year. These programs reflect the business’s broader ambition to extend gene-editing therapies to cancer and immune-mediated conditions.

While we acknowledge the risk and potential of CRSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRSP and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.